The main aim of this study is to understand how the body absorbs, processes, and removes (known as pharmacokinetics or PK) TAK-881 and HyQvia, after they are given as a single injection under the skin in healthy adults.
Study participants will receive a single dose of TAK-881 or HyQvia on Day 1.
During the study, participants will need to stay at the clinic for 8 days followed by 8 ambulatory follow up visits till Day 85.
Protocol Amendment History
4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-20; most recent amendment 2026-05-22.
Status change: Recruiting → Completed2025-08-14
Status change: Not Yet Recruiting → Recruiting2025-05-06